Antigen spreading was evaluated in a subset of Phase 2 patients to assess the ability of ELI-002 7P to broaden immune responses to personalized tumor neoantigens not present in the targeted immunotherapy87% (13/15) of evaluated patients demonstrated induction of T cell responses to tumor neoantigens beyond mKRAS following ELI-002 7P therapyThe induction of non-mKRAS antigen-specific T cell responses supports the potential for ELI-002 7P to generate a broader, more adaptable, and personalized anti-tumor resp ...

Core Insights - Elicio Therapeutics has appointed Marc J. Wolfgang as Chief Technology Officer, bringing over 30 years of biopharmaceutical leadership experience [1][2][3] Company Overview - Elicio Therapeutics is a clinical-stage biotechnology company focused on developing novel immunotherapies for high-prevalence cancers, including mKRAS-positive pancreatic and colorectal cancers [4] - The company aims to leverage its Amphiphile ("AMP") technology to enhance cancer-specific T cell responses, promoting durable cancer immunosurveillance [4] - Elicio's lead program, ELI-002, targets common KRAS mutations found in approximately 25% of all solid tumors and is currently in a randomized clinical trial for mKRAS-positive pancreatic cancer [4] Leadership and Expertise - Marc J. Wolfgang has extensive experience in manufacturing, CMC strategy, and operations across various modalities, including cell therapy and RNA-based medicines [2][3] - His previous roles include Senior Vice President at Sail Biomedicines and Vice President of U.S. Manufacturing at BioNTech, where he oversaw critical manufacturing and supply chain operations [2] Strategic Goals - The company is preparing for late-stage development and commercial-scale execution of ELI-002, with a primary disease-free survival analysis expected in the first half of 2026 [3] - Elicio plans to expand ELI-002 to other indications, including mKRAS-positive lung cancer, and is developing additional off-the-shelf immunotherapy candidates targeting BRAF-driven cancers and p53 hotspot mutations [4]

Core Insights - Elicio Therapeutics is presenting new immunogenicity data from its Phase 2 AMPLIFY-7P trial of ELI-002 for mKRAS-driven pancreatic cancer at the SITC Annual Meeting [1] - The company aims to develop off-the-shelf immunotherapies targeting prevalent cancers, leveraging its proprietary AMP technology to enhance T cell responses [3][4] Company Overview - Elicio Therapeutics is a clinical-stage biotechnology company focused on novel immunotherapies for high-prevalence cancers, including mKRAS-positive pancreatic and colorectal cancers [3] - The company's lead product candidate, ELI-002, targets common KRAS mutations found in approximately 25% of all solid tumors [4][5] - Elicio's AMP technology is designed to improve the education and activation of cancer-specific T cells, promoting durable cancer immunosurveillance [3][7] Clinical Trials and Data - ELI-002 is currently being studied in a randomized clinical trial for patients with mKRAS-positive pancreatic cancer who are at high risk of relapse after standard therapy [3][5] - The AMPLIFY-201 Phase 1 trial data showed a median recurrence-free survival of 16.3 months and a median overall survival of 28.9 months for the full study population [3] - Elicio plans to expand ELI-002 to other indications, including mKRAS-positive lung cancer [3] Presentation Details - The late-breaking abstract presentation titled "AMPLIFY-7P Phase 2: T cell responses induced by ELI-002 7P" will be presented by Dr. Lisa McNeil on November 7, 2025 [2] - Another poster presentation titled "AMP-Immunomodulator therapy controls growth and eradicates syngeneic solid tumors" will be presented by Dr. Martin Steinbuck on November 8, 2025 [3]

Core Insights - Elicio Therapeutics has reported preliminary findings from the Phase 2 AMPLIFY-7P trial, indicating that specific Human Leukocyte Antigen (HLA) types do not affect the ability of patients to generate robust mKRAS-specific T-cell responses after treatment with ELI-002 7P [1][3][5] Group 1: Trial Findings - Among 89 patients treated with ELI-002 7P, a total of 1,132 unique HLAs were identified, demonstrating significant genetic diversity within the study population [2][5] - 99% (88 out of 89) of patients assessed for HLA background showed mKRAS-specific T-cell responses post-treatment, suggesting broad applicability of ELI-002 7P for pancreatic ductal adenocarcinoma (PDAC) patients [5][6] - The findings align with recent studies indicating that mKRAS antigens can be presented across a wide range of HLA types, supporting the potential for ELI-002 7P to address a critical unmet need in cancer treatment [2][3] Group 2: Product and Technology Overview - Elicio's lead product candidate, ELI-002, is an off-the-shelf immunotherapy targeting common KRAS mutations, which are responsible for approximately 25% of all solid tumors [4][7] - The AMP technology utilized in ELI-002 aims to enhance the activation and amplification of cancer-specific T cells, potentially leading to durable cancer immunosurveillance [4][9] - Elicio plans to expand the application of ELI-002 to other indications, including mKRAS-positive lung cancer and additional mKRAS-driven cancers, indicating a broad pipeline of therapeutic candidates [6][8]